MICROVIABLE THERAPEUTICS
Mission & Vision
Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable’s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients’ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.
NEWS
You can follow the latest news of MicroViable in this section
Past, present, and future of microbiome-based therapies
Technological advances in studying the human microbiome in depth have enabled the identification of microbial [...]
Inmunobiota: A co-creation project of Microviable and the Institute of Catalysis and Petroleochemistry (ICP-CSIC)
Inmunobiota is one of the projects selected in CSIC-COCREA that seeks to develop products based [...]
International Childhood Cancer Day 2024
Today, February 15, is International Childhood Cancer Day (ICCD), a global collaborative campaign to raise [...]
CONTACT
Get in touch with us for any questions using the following contact form.